Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
1(20%)
Results Posted
67%(2 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_1
1
20%
Ph phase_2
4
80%

Phase Distribution

1

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
4(80.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(3)
Terminated(1)

Detailed Status

Completed3
Active, not recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
75.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (20.0%)
Phase 24 (80.0%)

Trials by Status

active_not_recruiting120%
completed360%
terminated120%

Recent Activity

1 active trials
Showing 5 of 5
active_not_recruitingphase_2

ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer

NCT02972060
completedphase_2

A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer

NCT03314324
terminatedphase_2

ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.

NCT02933801
completedphase_1

Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

NCT01317641
completedphase_2

Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001

NCT01429064

Clinical Trials (5)

Showing 5 of 5 trials
NCT02972060Phase 2

ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer

Active Not Recruiting
NCT03314324Phase 2

A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer

Completed
NCT02933801Phase 2

ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.

Terminated
NCT01317641Phase 1

Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

Completed
NCT01429064Phase 2

Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5